logo
  

FLIR Systems Gets $27.1 Mln Orders From U.S. DoD To Support DR SKO Program

FLIR Systems Inc. (FLIR) said Monday that it has received the first full-rate production orders under a five-year indefinite delivery, indefinite quantity contract from the U.S. Department of Defense to support the Nuclear, Biological, and Chemical Dismounted Reconnaissance Sets, Kits, and Outfits or DR SKO program.

The contract is for FLIR's integrated chemical, biological, radiological, nuclear, and explosives or CBRNE threat response system and related spares and services. Initial delivery orders totaling $27.1 million were received for systems and support.

The DR SKO program, in development since 2008, is a joint-service, Department of Defense initiative centered on CBRNE threat detection systems that will be utilized by the Army, Navy, Air Force, Marines, and Civil Support Teams.

The FLIR DR SKO system provides an integrated set of CBRNE detection, identification, sample collection, testing, and personal safety kits that allow personnel to perform site assessment and consequence management missions.

Production under the contract is expected to be performed out of FLIR's facility in Elkridge, MD, and fulfillment of these delivery orders is expected to occur throughout 2015.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT